Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy

Launched by XIANGYA HOSPITAL OF CENTRAL SOUTH UNIVERSITY · Aug 3, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether a medication called idebenone can help prevent epilepsy in patients who have had a stroke. Epilepsy is a condition that can cause seizures, and some people may develop it after experiencing a stroke. In this trial, patients will be divided into three groups: one group will take idebenone for 14 days shortly after their stroke, another group will take it for 3 months, and the third group will not receive the medication at all.

To participate, individuals must have been admitted to the hospital within 24 hours of stroke symptoms and have a confirmed stroke diagnosis. They should also be able to follow instructions and agree to participate by signing a consent form. However, people who had epilepsy before their stroke or have certain serious health issues that could lead to seizures will not be eligible. This study is currently looking for participants, and it aims to see if idebenone can effectively reduce the risk of developing epilepsy after a stroke.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed with stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, intracranial venous sinus thrombosis, etc.) after relevant examinations;
• • Able to cooperate with the inspection;
• • Sign the informed consent form.
• Exclusion Criteria:
• • History of epilepsy before stroke;
• • A history of serious comorbidities that may lead to seizures (including malignant tumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);
• • Secondary stroke caused by head trauma or surgery;
• • Other patients that the researchers think need to be excluded.